At 01:06 pm, Aarti Industries was trading 7 per cent higher at Rs 1,376, as compared to 1.3 per cent decline in the S&P BSE Sensex. The trading volumes on the counter jumped over eight-fold with a combined 2.05 million equity shares changing hands on the NSE and BSE.
Aarti Industries is a leading speciality chemicals company in Benzene-based derivatives with integrated operations and high-level of cost optimization. The company’s plants located in western India with proximity to ports: 13 for speciality chemicals; 5 for pharma (2 USFDA and 3 WHO/GMP). The company has a diversified product portfolio with end users in pharma, agrochemicals, specialty polymers, paints & pigments.
In the October-December quarter (Q3FY21), the company’s revenue grew by 10 per cent year on year (YoY), led by strong off-take from pharma segment, which grew by around 32 per cent YoY. Earnings before interest, taxes, depreciation, and amortization (Ebitda) margins improved by 50 basis points YoY to 24 per cent due to lower cost and profit after tax grew by 18 per cent YoY.
The management said the company is well positioned to meet guidance of delivering profits in line with last year despite the exceptional disruption seen in FY21. Underlying the reported numbers is a return of demand from regular markets and long-standing relationships, which is reflected in margin improvement and gradually resuming normalcy during the quarter.
Management has also indicated the capital expenditure momentum will continue in the near to medium term including project for long term contracts, NCB & Pharma expansion. The new downstream products are of import substitution opportunities worth Rs 1,000 crore.
Analysts at Geojit Financial Services expect the company's specialty chemical margins to improve going ahead, led by better improved off-take from its discretionary portfolio. "We remain constructive on Aaarti Industries’ as execution of multiyear contracts, revival in volumes from Specialty chemicals and improved outlook on account issues in China, will benefit the company in the medium term," the brokerage firm said in Q3FY21 results update.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in